Related Experiment Videos
Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin
K A Wise1, M Bedford, S S Wadhwa
1Wollongong Campus, Illawarra Regional Hospital, Illawarra Area Health Service, New South Wales.
Abstract:
A case of meningitis caused by a strain of Streptococcus pneumoniae (SPn) showing high level resistance to penicillin is described. The patient responded to a combination of high dose penicillin and ceftriaxone. After reviewing the Australian situation and the world literature, we propose that empiric treatment of SPn meningitis in Australia should consist of high dose penicillin plus a third generation cephalosporin, with appropriate modification once the identification of the organism and its susceptibilities are confirmed.
Insights
A case of meningitis caused by penicillin-resistant Streptococcus pneumoniae (SPn) was treated successfully with high-dose penicillin and ceftriaxone. Empiric treatment for SPn meningitis in Australia should combine high-dose penicillin with a cephalosporin.
Area of Science:
- Infectious Diseases
- Microbiology
- Clinical Medicine
Background:
- Meningitis remains a significant cause of morbidity and mortality worldwide.
- Emergence of antibiotic resistance in bacterial pathogens poses a critical challenge to effective treatment.
- Streptococcus pneumoniae is a leading cause of bacterial meningitis.
Observation:
- A case of meningitis was caused by a Streptococcus pneumoniae strain exhibiting high-level penicillin resistance.
- The patient's clinical condition improved with a therapeutic regimen involving high-dose penicillin and ceftriaxone.
Findings:
- The combination therapy of high-dose penicillin and ceftriaxone demonstrated efficacy against the penicillin-resistant Streptococcus pneumoniae strain.
- Review of Australian and global literature supports this combination approach for empiric treatment.
Implications:
- Empiric treatment guidelines for Streptococcus pneumoniae meningitis in Australia should be updated.
- The proposed regimen of high-dose penicillin plus a third-generation cephalosporin offers a viable strategy for managing resistant meningitis.
- Antimicrobial stewardship and susceptibility testing are crucial for optimizing patient outcomes.